Oncolytics Biotech, Inc. (TSX: ONC NASDAQ: ONCY) engages in the discovery and development of pharmaceutical products for the treatment of a wide variety of human cancers. Founded in 1998 in Alberta, Canada, the company was initially formed to research the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway, a common characteristic present in the family of genetic cell defects leading to cancer.

Reovirus, or Respiratory Enteric Orphan virus, is generally believed to inhabit the respiratory and bowel systems in humans, and can be found naturally in sewage and water supplies. One of the obstacles with reovirus is that there are no clear symptoms from infections. The link that developed to its cancer-killing ability was established after the reovirus was discovered to reproduce well in various cancer cell lines.

Tumors bearing an activated Ras pathway are deficient in their ability to …

Marshall Edwards, a subsidiary of the Australian pharmaceutical company, Novogen Limited, was formed with the specific intent of increasing the focus on an important new oncological discovery known as multiple signal transduction regulators (MSTRs).

Novogen scientists discovered these regulators, and brought Marshall Edwards onboard to develop the products commercially. The main MSTR, called Phenoxodiol, is currently undergoing Phase III clinical testing in the US, Europe, and Australia. The drug is being developed for the treatment of both early and late-stage prostate and cervical cancer, as well as ovarian cancers that have proven to be resistant to chemotherapy.

Phenoxodiol promotes the death of cancer cells by inhibiting harmful proteins which prevent apoptosis (the natural process of self-destruction in certain cells). The drug can be used in conjunction with other, more traditional forms of treatment.

A feeling of cautious excitement comes with every possibility of reducing or eradicating cancerous cells. What sets Marshall

Taplmmune, Inc. (TPIM.OB) is a developer of new innovative therapeutics and vaccines in the oncology and infectious disease areas. The company’s therapeutics and vaccines are based on technologies that utilize transporters associated with Antigen Processing (TAP). TAP therapy offers improvements in efficacy as well as reduced side effects and a boost in body defenses.

Teplmmune’s TAP cancer vaccine primarily moves antigens to the surface of cells and restores TAP proteins and the immune system’s ability to recognize and destroy cancer cells. The TAP molecule has also shown abilities to enhance the potency of vaccines against infectious diseases.

Taplmmune’s TAP has already been through clinical studies and has proven several forms of cancer that are deficient to the vaccine. Some cancers deficient to the vaccine include melanoma, colon, cervical, lung, prostate, breast and ovarian. The company began their preclinical testing of TAP in 2007, and is currently

BSD Medical Corp. (Nasdaq: BSDM) is part of the global fight against cancer. The company develops systems for cancer therapies requiring precision-focused heat through microwave technologies. Today the company announced its European distributor was awarded a contract from Azienda Ospedaliera Institui Ospitalieri Di Verona (the Institute) to replace its existing hyperthermia system with BSD’s BSD-2000/3D system.

The BSD-2000/3D deep regional hyperthermia system is scheduled for delivery in August 2008, and will replace the Institute’s current system, which has been used since 1996. The BSD-2000/3D will be the first of its kind in Italy, and the 15th utilized in Europe.

“We are pleased to further expand our activities in the field of clinical hyperthermia, the single most potent radiation sensitizer available. We are looking forward to close working relationships with all of the ESHO [European Society for Hyperthermic Oncology] member institutes in advancing hyperthermia cancer treatment,” Dr. Sergio Maluta, head of the

TapImmune, Inc. (OTCBB: TPIM) announced that their TAP incorporated vaccine for the treatment of cancer was recently reviewed by a third party research article in the Journal of Investigative Dermatology, which confirmed that the company’s vaccine should be considered as a therapy for cancer.

The article, entitled, “Restoration of the Expression of Transporters Associate with Antigen Processing in Human Malignant Melanoma Increases Tumor-Specific Immunity,” was published in advance online on April 3, 2008. TapImmune is a biotechnology company that specializes in the development of immunotherapeutics for cancer and vaccines for infectious diseases, and the company’s stock rose 37.10% in Monday’s trading.

The company’s promising TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells. TAP, which stands for Transporters with Antigen Processing, are proteins responsible for supplying tumor-associated antigens (markers) and viral antigens to the surface of infected cells. Without